Nanoformulation of paclitaxel to enhance cancer therapy

Gu, Quanrong; Jin, Xing; Huang, Mingxian; Zhang, Xiaojing; Chen, Jie

doi:10.1177/0885328212446822

Cited by 30 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro anticancer activity of SpHL-PTX was clearly higher than that verified for free PTX in both cell lines. Results obtained for free PTX corroborate others previously described [11,38]. Moreover, formulations without PTX showed no significant activity.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Experimental design of a liposomal lipid system: A potential strategy for paclitaxel-based breast cancer treatment

Barbosa¹,

Monteiro

Carneiro³

et al. 2015

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

“…This increase in the cytotoxicity observed after the treatment with SpHL-PTX suggests enhanced uptake of the liposomal vesicles compared with PTX in its free form, as stated by previous studies such as Gu et al. [38]. Also, pH-sensitive liposomes have been suggested to be more efficiently internalized than the free drug [39].…”

Section: Discussionsupporting

confidence: 56%

Experimental design of a liposomal lipid system: A potential strategy for paclitaxel-based breast cancer treatment

Barbosa¹,

Monteiro

Carneiro³

et al. 2015

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

“…The modification of taxane drugs is a continued area of research, with aims to produce molecules of greater efficacy, reduced side effects (e.g. nausea, pain, alopecia, myalgia and hypersensitivity reactions) (Urquhart, ), greater solubility (Yared and Tkaczuk, ), transport capacity (Fitzgerald et al ., ; Gu et al ., ) and minimizing progressive drug resistance associated with over‐expression of III β‐tubulin (English et al ., ), HER‐2 (Murray et al ., ), ninein‐like protein (Zhao et al ., ), SEPT9 (Chacko et al ., ) and drug‐efflux pumps (Froidevaux‐Klipfel et al ., ).…”

Section: Introductionmentioning

confidence: 99%

High Throughput Screening of Natural Products for Anti‐mitotic Effects in MDA‐MB‐231 Human Breast Carcinoma Cells

Mazzio

Badisa

Mack

et al. 2013

Phytotherapy Research

View full text Add to dashboard Cite

Some of the most effective anti-mitotic microtubule-binding agents, such as paclitaxel (Taxus brevifolia) were originally discovered through robust NCI botanical screenings. In this study, a high-through microarray format was utilized to screen 897 aqueous extracts of commonly used natural products (0.00015–0.5 mg/ml) relative to paclitaxel for anti-mitotic effects (independent of toxicity) on proliferation of MDA-MB-231 cells. The data obtained showed that less than 1.34 % tested showed inhibitory growth (IG50) properties <0.0183 mg/ml. The most potent anti-mitotics (independent of toxicity) were Mandrake root (Podophyllum peltatum), Truja Twigs (Thuja occidentalis), Colorado desert mistletoe (Phoradendron flavescens), Tou Gu Cao Speranskia Herb (Speranskia tuberculata), Bentonite Clay, Bunge Root (Pulsatilla chinensis), Brucea Fruit (Brucea javanica), Madder Root (Rubia tinctorum), Gallnut of Chinese Sumac (Melaphis chinensis), Elecampane Root (Inula Helenium), Yuan Zhi Root (Polygala tenuifolia), Pagoda Tree Fruit (Melia Toosendan), Stone Root (Collinsonia Canadensis) and others such as American Witchhazel, Arjun and Bladderwrack. The strongest tumoricidal herbs identified from amongst the subset evaluated for anti-mitotic properties were wild yam (Dioscorea villosa), beth-root (Trillium Pendulum) and alkanet-root (Lithospermum canescens). Additional data was obtained on a lesser-recognized herb: (Speranskia tuberculata) which showed growth inhibition on BT-474 (human ductal breast carcinoma) and Ishikawa (human endometrial adenocarcinoma) cells with ability to block replicative DNA synthesis leading to G2 arrest in MDA-MB-231 cells. In conclusion, these findings present relative potency of natural anti-mitotic resources effective against human breast carcinoma MDA-MB-231 cell division.

show abstract

“…These results reveal that the biotin-conjugated nanoparticles could improve the selective delivery of PTX into cancer cells via interactions with overexpressed biotin receptors on the surfaces of cancer cells. Gu et al [69] prepared PTX-loaded nanoparticles, and a cytotoxicity assay was performed using breast cancer MCF-7 and cervical cancer HeLa cells. The half maximal inhibitory concentrations (IC 50 ) of PTX nanoparticles and PTX were found to be 8.5 ± 0.3 and 14.0 ± 0.7 ng/ml at 48 h and 3.5 ± 0.4 and 5.2 ± 0.5 ng/ml at 72 h across several runs.…”

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

Possible role of nanocarriers in drug delivery against cervical cancer

Gupta

2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Introduction: Cervical cancer is the second most common cancer and the largest cancer killer among women in most developing countries including India. Although, various drugs have been developed for cervical cancer, treatment with these drugs often results in a number of undesirable side effects, toxicity and multidrug resistance (MDR). Also, the outcomes for cervical cancer patients remain poor after surgery and chemo radiation. Methods: A literature search (for drugs and delivery systems against cervical cancer) was performed on PubMed and through Google. The present review discuss about various methods including its current conventional treatment with special reference to recent advances in delivery systems encapsulating various anticancer drugs and natural plant products for targeting towards cervical cancer. The role of photothermal therapy, gene therapy and radiation therapy against cervical cancer is also discussed. Results: Systemic/targeted drug delivery systems including liposomes, nanoparticles, hydrogels, dendrimers etc. and localized drug delivery systems like cervical patches, films, rings etc. are safer than the conventional chemotherapy which has further been proved by the several drug delivery systems undergoing clinical trials. Conclusion: Novel approaches for the aggressive treatment of cervical cancer will optimistically result in decreased side effects as well as toxicity, frequency of administration of existing drugs, to overcome MDR and to increase the survival rates.

show abstract

Nanoformulation of paclitaxel to enhance cancer therapy

Abstract: paclitaxel-loaded nanoparticles greatly improved the physicochemical properties of paclitaxel without modifying its chemical structure, allowing for deep-site cancer drug delivery and enhancing the drug therapeutic efficiency.

Cited by 30 publications

References 30 publications

Experimental design of a liposomal lipid system: A potential strategy for paclitaxel-based breast cancer treatment

Experimental design of a liposomal lipid system: A potential strategy for paclitaxel-based breast cancer treatment

High Throughput Screening of Natural Products for Anti‐mitotic Effects in MDA‐MB‐231 Human Breast Carcinoma Cells

Possible role of nanocarriers in drug delivery against cervical cancer

Contact Info

Product

Resources

About